Juengel, E.; Schnalke, P.; Rutz, J.; Maxeiner, S.; Chun, F.K.-H.; Blaheta, R.A.
Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment. Biomedicines 2021, 9, 1630.
https://doi.org/10.3390/biomedicines9111630
AMA Style
Juengel E, Schnalke P, Rutz J, Maxeiner S, Chun FK-H, Blaheta RA.
Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment. Biomedicines. 2021; 9(11):1630.
https://doi.org/10.3390/biomedicines9111630
Chicago/Turabian Style
Juengel, Eva, Pascal Schnalke, Jochen Rutz, Sebastian Maxeiner, Felix K.-H. Chun, and Roman A. Blaheta.
2021. "Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment" Biomedicines 9, no. 11: 1630.
https://doi.org/10.3390/biomedicines9111630
APA Style
Juengel, E., Schnalke, P., Rutz, J., Maxeiner, S., Chun, F. K.-H., & Blaheta, R. A.
(2021). Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment. Biomedicines, 9(11), 1630.
https://doi.org/10.3390/biomedicines9111630